COVID-19 in children: Should we be worried?

C L Hendricks,1 FCPaed (SA), MMed (Paediatrics and Child Health), Cert Clin Haematology (SA) Paed; R J Green,2 PhD, DSc

1 Department of Immunology, Institute for Cellular and Molecular Medicine and SAMRC Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa
2 Department of Paediatrics and Child Health, Steve Biko Academic Hospital and Faculty of Health Sciences, University of Pretoria, South Africa

Reports indicate that children infected with SARS-CoV-2 have thus far presented with less severe disease than adults. Anxiety regarding a greater ability to transmit the virus is largely unfounded and has played a significant role in the decision to allow children to return to school. In some patients, however, especially in infants and in those with underlying comorbidities, severe disease must be anticipated and planned for accordingly. The most relevant severe clinical presentation in addition to the established respiratory complications, is that of a multisystem inflammatory disorder, with features resembling Kawasaki disease. The impact of the pandemic on the economic and social wellbeing of children, including food insecurity and care when parents are ill, cannot be ignored. During this pandemic, it is imperative to ensure access to routine and emergency medical services to sick children. In so doing, potentially devastating medical and socioeconomic consequences can be mitigated.

Why do children have less severe disease than adults?

Possible explanations are:

- **Qualitative differences in response:** Children are known to have diminished innate and adaptive immune responses, which lead to decreased cytokine responses, especially in neonates, compared with adults. They may therefore mount a blunted immune response or respond differently to adults.

- **Receptor:** Children are thought to possess less mature and therefore less functional forms of the ACE2 receptor, the primary SARS-CoV-2 receptor, as described above. A recently published retrospective review examining the expression of ACE2 in the nasal epithelium of a previous cohort of patients (who had been enrolled to detect nasal biomarkers of asthma), found significantly lower levels of ACE2 in children <10 years old. This finding may decrease the ability to acquire SARS-CoV-2 infection in the nasal epithelium, but does not necessarily relate to decreased expression in the lung epithelium, as gene expression in these two areas differs. The cluster of differentiation 147 (CD147) has also been shown to act as a receptor for SARS-CoV-2 in T-cell lines and cells of epithelial origin. CD147, interestingly, is also the putative receptor for HIV-1, measles and malaria merozoites entry into erythrocytes. The expression analysis demonstrated high CD147 gene expression in children of black African origin compared with white adolescents and adults. Whether this will reflect in an increased risk of infection in black African children is currently not known.

- **Competition with other viruses:** Children usually have many viruses lining their respiratory tracts and COVID-19 may be competing for engagement with receptors in this regard. The presence of other viruses may also mean that high antibody levels against viruses are present.

- **Recent bacillus Calmette-Guérin (BCG) vaccine:** Association studies have suggested that the routine BCG vaccine, administered at birth, may help to protect from SARS-CoV-2 infection as a result of ‘trained innate immunity’. Children who have recently been vaccinated may have greater protection.

PubMed and other databases were thoroughly investigated using the search words ‘COVID-19 and children’. The authors then evaluated published studies on the epidemiology, prevalence, transmission and diverse clinical presentations in children with COVID-19 from these sources.

Within a few months, COVID-19, caused by SARS-CoV-2, claimed the lives of 708 036 people worldwide (6 August 2020). Entering the body through the respiratory mucosa and conjunctiva, the virus binds to the angiotensin-converting enzyme 2 (ACE2) present in the nasal passages, lung and intestines. ACE2 is responsible for converting angiotensin II into angiotensin (1-7) in the renin-angiotensin-aldosterone system (RAAS) for blood pressure control. The resulting excessive accumulation of angiotensin II results in vasoconstriction, inflammation and fibrosis.

Viral entry into cells induces a protective immune response in some people, while in others a ‘cytokine storm’, referring to massive release of pro-inflammatory cytokines, ensues. This cytokine storm causes tissue damage and the clinical picture of acute respiratory distress syndrome (ARDS), the leading cause of COVID-19-related deaths, in patients unable to contain the infection.

Throughout the development and establishment of this pandemic, children have certainly been reported to be infected from the start, but have been noted to have less severe disease than adults. The incidence has consistently been reported as 1 - 5%.[9-12] Some of the paediatric reports from China, Italy and the USA are summarised in Table 1. These indicate that COVID-19 remains a less dangerous disease than adults.

Much information affecting the paediatric population, however, remains elusive, which provides the backdrop against which conflicting reports cause confusion and fear. As the disease has evolved, many more pertinent questions related to children have been raised: Can the virus be contracted through intrauterine spread? Can children go to school? What is the actual risk of severe disease? What is the economic impact of COVID-19 in children? Some of these questions are addressed below.

---

S Afr Med J 2020;110(9):864-868. https://doi.org/10.7196/SAMJ.2020.v110i9.15023

Corresponding author: C L Hendricks (candice_hendricks@outlook.com)
Transmission of the virus by children

Reports indicate that asymptomatic disease,[9,11,12] mild disease in the presence of persistently positive SARS-CoV-2 polymerase chain reaction (PCR) results,[14] and viral shedding in the stool,[12,16,26] can be seen in children. Children can therefore potentially transmit the virus through respiratory secretions, as well as through facial-oral spread. However, early reports from China suggesting that children may be the primary source of spread of SARS-CoV-2, resembling transmission characteristics of influenza, have not proven to be true.[25] In countries with widespread community testing, such as South Korea and Iceland, with adequate contact tracing, children were found to be significantly under-represented. In population screening in Iceland, no children <10 years of age were found to be positive for SARS-CoV-2 compared with 0.8% of the general population,[26] and in Vo, Italy, no children <10 years were found to be positive, compared with 2.6% of the general population.[27]

Evidence from contact tracing in Japan found lower attack rates in children,[25] and a study in Guangzhou, China, found a much lower secondary attack rate for children than adults (odds ratio (OR) 0.23).[28] In a study in the Netherlands, no child <19 years of age could be traced as a source of infection in an adult.[29]

These facts have a bearing on continued ‘lockdown’, especially of children, and the number of unintended collateral damage consequences they experience.

Severe clinical presentations

Although children rarely progress to severe disease, the potential does exist and multiple reports of severe disease have been published. Apart from the respiratory complications that are well described, small cohorts of children in Europe, the UK[31] and the USA[32] were found to present with a widespread inflammatory syndrome, resembling atypical Kawasaki disease or toxic shock syndrome. Kawasaki disease refers to a very rare disorder of unknown cause,[33] synonymous with mucocutaneous lymph node syndrome.[34] Patients present with a combination of features, such as an unrelenting fever for >5 days with mucocutaneous manifestations (conjunctivitis, changes in the tongue or oral cavity, oedema of the hands and feet followed by desquamation, a rash and cervical lymph node involvement).[34]

The cardiac manifestations are related to a microvasculitis leading to aneurysms of the coronary arteries in up to 20% of affected patients, although other arteries in the body may also be affected.[33]

Children with COVID-19 may present with some, but not all of these features. Further evidence for the association was an initial review of 10 cases of the Kawasaki-like disease in Italy, which revealed a 30-fold increase in such cases in the COVID-19 era compared with the 5 years preceding COVID-19.[30] The majority of these children had positive serological testing for SARS-CoV-2 and not PCR. This indicates that primary infection is not the cause and suggests that host immune response against the virus is the driving pathogenesis.[33,35,36] Further cohorts have included patients from the USA (3 reports; n=17,[37] n=95,[39] and n=186[30]), France (2 reports; n=21[40] and n=16[41]) and the UK (2 reports: n=8[25] and n=58[42]). Although a large proportion of these patients required intensive care, the literature indicates that outcomes are very encouraging, with a mortality rate of 2 - 4%.[36]

In this regard, the Royal College of Paediatrics and Child Health (RCPCH) refers to ‘Paediatric multi-system inflammatory syndrome potentially associated with COVID-19’. A case definition has been

---

**Table 1. Summary of paediatric reports**

| Report origin | Report date | Cohort, n | Transmission, % | Clinical signs | Incidence of severity, % | Mortality rate (at time of publication), %* |
|---------------|-------------|-----------|-----------------|---------------|-------------------------|-------------------------------------------|
| China[10]     | 25 March 2020 | 728       | Not reported    | Fever, respiratory symptoms | Asymptomatic, 12.9 (severe/critical, 2.9) | n=1 (not reported whether SARS-CoV-2 confirmed) |
| China[10]     | 25 April 2020 | 36        | Family, 89     | Fever, cough | Asymptomatic, 28 (severe/critical, 0) | 0 |
| USA[10]       | 10 April 2020 | 2 572†    | Home or community, 91 | Fever, cough, SOB | Asymptomatic cases unknown Hospitalisations, 5.7 - 20† (severe/critical, 0.58 - 2.00) | 0.001 (n=3) |
| China[10]     | 23 April 2020 | 171       | Family, 90     | Fever, cough, pharyngeal erythema | Asymptomatic, 15.8 Rate of hospitalisation not provided (severe/critical, 1.8) | 0.005 (n=1) |
| Italy[10]     | 1 May 2020    | 100       | Outside family/ unknown, 55 | Fever, cough, SOB | Asymptomatic, 21 Hospitalisations, 38 (severe/critical, 2) | 0 |
| USA[10]       | 6 May 2020    | 177       | Not reported    | Fever, cough, SOB | Asymptomatic infections not provided Hospitalisations, 25 (severe/critical, 5) | 0 |
| China[10]     | 3 June 2020   | 157       | Not reported    | Fever, cough | Asymptomatic, 30 Hospitalised cohort, 100 (severe/critical, 5.7) | 0.01 |

SOB = shortness of breath.
†Unless otherwise indicated.
‡A large proportion of these patients did not have complete records.
§Estimated range: Hospitalisation status was known for only 29% of children.
‡A small proportion of these patients did not have complete records.
*All patients with symptoms or signs, irrespective of severity of disease were admitted.
Intrauterine spread

The first infected neonate, diagnosed soon after birth, was reported from China in February 2020[7] and has been the catalyst for the determination of whether the virus is able to cross the placenta. Chen et al.[8] reported negative SARS-CoV-2 PCR results from amniotic fluid, cord blood and neonatal throat swabs from 6 pregnant patients who tested positive for SARS-CoV-2. The small sample size and the enrolment of mothers while in the third trimester are important confounders. These findings are supported by Li et al.[9] where serial sampling in an exposed neonate, including urine, faeces and blood, showed persistent absence of SARS-CoV-2, and a further cohort of 10 neonates from infected mothers also tested negative.[10] On the other side of the spectrum, SARS-CoV-2 RNA has been found on the fetal side of the placenta in 2 COVID-19-positive mothers and blood, showed persistent absence of SARS-CoV-2, and a further cohort of 10 neonates from infected mothers also tested negative.[11] These findings suggest that the potential for intrauterine spread does exist. This argument is further strengthened by the presence of virus-specific IgM in 2 neonates from COVID-19-positive mothers.[12] In spite of these reports, the RCPCH,[13] a small cohort of SARS-CoV-2-positive patients with underlying kidney disease managed with immunosuppressive therapy was recently found to present with mild disease, with no patients requiring ICU admission. Echoing these sentiments was a report from Lombardy, Italy, where 5 paediatric oncology patients presented with self-limiting disease.[14] Whether these reports will hold true in the months to come remains to be seen, but nonetheless, social distancing, hand washing and other strict infection control measures (as with all patients) must remain a priority, while ensuring that patients are able to access essential medication.

Should children go to school?

After the initial strict lockdown in South Africa (SA), conversations regarding the safety of returning to school have sparked controversy, as fears of rapid viral spread were brought to light. Continued formulation of new RCPCH,[15] guideline to assist with treating such patients, summarised in Table 2.[16] Following on from these cases, the Centers for Disease Control and Prevention (CDC) has also provided a name for and definition of the illness (Table 3).[17] Both definitions include severely ill patients only, and possible risk, excluding patients who present with milder disease.[18]

Patients presenting with this condition have to be referred for specialist care in a high-care or intensive care setting for treatment. Medical management has included immunoglobulins, corticosteroids and aspirin; however, clinical trials will determine the optimum treatment algorithm. All medical personnel are urged to have a high index of suspicion in all patients with possible SARS-CoV-2 exposure to ensure prompt treatment.

Table 2. RCPCH case definition of paediatric multisystem inflammatory syndrome potentially associated with COVID-19

| Definition                                                                 | Criteria                                                                 |
|---------------------------------------------------------------------------|--------------------------------------------------------------------------|
| A child presenting with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopenia) and evidence of single- or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features (full list supplied by RCPCH),[19] which may include children fulfilling full or partial criteria for Kawasaki disease | RCPCH = Royal College of Paediatrics and Child Health; CRP = C-reactive protein. |
| Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice) | |
| SARS-CoV-2 PCR testing may be positive or negative                         | |

Table 3. CDC case definition for multisystem inflammatory syndrome in children

| Definition                                                                 | Criteria                                                                 |
|---------------------------------------------------------------------------|--------------------------------------------------------------------------|
| A patient aged <21 years presenting with fever,* laboratory evidence of inflammation,* and evidence of clinically severe illness requiring hospitalisation, with multisystem (≥2) organ involvement (cardiac, renal, respiratory, haematological, gastrointestinal, dermatological or neurological),* and | CDC = Centers for Disease Control and Prevention; RT-PCR = reverse transcription polymerase chain reaction. |
| No alternative plausible diagnoses; and                                   | *Fever ≥38°C for ≥24 hours, or; subject fever lasting ≥24 hours. |
| Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms | |

*Including, but not limited to 1 of the following: an elevated C-reactive protein, erythrocyte sedimentation rate, fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase or interleukin 6, elevated neutrophils, reduced lymphocytes and low albumin.
school closure has, however, been found to not only have economic consequences but also psychological consequences for the child.\textsuperscript{[64]} Based on the evidence in the literature, the SA Paediatric Association (SAPA) issued a statement, advocating for the return of children to school.\textsuperscript{[57]} The statement also provides guidelines for the implementation of learning practices, while minimising infection risk. Particular emphasis is placed on the benefit for poor children, who not only have no or limited access to online learning but who additionally benefit from school feeding schemes. As significant inequalities exist in the SA schooling system in terms of resources, schools in under-resourced areas will have to be provided with the necessary support to ensure a safe school environment.

**Face masks**

According to the CDC, face masks are not recommended for children <2 years old, because the risk of suffocation is higher in younger children.\textsuperscript{[59]} The SAPA position statement on the return of children to school has advised that masks should be used by children >4 years of age in a school setting.

**Collateral damage to children**

In a time of fear and anxiety, medical management of sick children should remain pragmatic and evidence based. Sick children, presenting with fever and cough, are being treated with empirical antibiotics, hydroxychloroquine and azithromycin by healthcare practitioners, even for mild and unproven COVID-19. These treatment interventions are not benign in children and lead to side-effects, antibiotic resistance and dysbiosis of the human microbiome.\textsuperscript{[39]} Hydroxychloroquine and azithromycin have no proven benefit in COVID-19 – certainly not in children.\textsuperscript{[61]}

Moreover, ‘lockdown’ has had unintended economic and social consequences for children. Children with acute and chronic conditions are prevented from accessing healthcare, leading to loss of routine immunisation opportunities, access to chronic medication and loss of feeding opportunities that are frequently provided at schools.\textsuperscript{[60]} Food insecurity, leading to an increase in malnutrition, is a very real concern, as is the potential lack of care in homes where parents become ill and require hospitalisation.

**The South African situation**

On 6 August 2020, SA had 529 877 cases and 9 298 deaths related to COVID-19.\textsuperscript{[22]} The latest report detailing the age breakdown of cases of paediatric multisystem inflammatory syndrome (PMIS) have also been recorded.

Although we may feel secure as international reports indicate a decreased risk of severe disease in children, SA has many unique factors to consider. The majority of our population is of black African ancestry. In the UK and USA, black African people (as well as other minorities) have been disproportionately affected by the pandemic.\textsuperscript{[64],[65]} Comorbidities and the comparatively low socioeconomic status of these persons are thought to put them at higher risk of disease, similar to our SA situation. Whether differential host immune responses to SARS-CoV-2 are thought to put them at higher risk of disease,

1. Shokredian LM, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr 2020;115(1):5-7. https://doi.org/10.1001/jamapediatr.2019.1948
2. John Hopkins University and Medicine. COVID-19 map – John Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html (accessed 6 August 2020).
3. Malviya JJ, Maggo CM, Mla LX, Nuovo GJ, Ruegen KR. Analysis of complement deposition and viral RNA in placenta of COVID-19 patients. Ann Diagn Pathol 2020;61:151. https://doi.org/10.1016/j.anndiagpath.2020.115130
4. Patel AB, Verma A, Naal ACE levels and COVID-19 in children. JAMA 2020;323(23):2386-2387. https://doi.org/10.1001/jama.2020.8966
5. Hirano T, Murakami M. COVID-19 A new virus, but a familiar receptor and cytokine release syndrome. Immunology 2020;32:371-375. https://doi.org/10.1111/imm.13502
6. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: The perspectives on immune responses. Cell Death Differ 2020;27(3):1431-1454. https://doi.org/10.1038/s41418-020-0330-3
7. Lu X, Gong M, Pang Y, Meng L, Liu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020;10(2):102-108. https://doi.org/10.1016/j.jpha.2020.03.001
8. Liu W, Zhang Q, Chen J, et al. Diagnosis of Covid-19 in children in early January 2020 in Wuhan, China. N Eng J Med 2020;382(14):1370-1371. https://doi.org/10.1056/NEJMoa2000277
9. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145(6):e20200702. https://doi.org/10.1542/peds.2020-0702
10. Buleh S, Gerike K, Hughes M, McNamara LA, Pabreza T, Teiff S. Coronavirus disease 2019 in children. United States. February 12 – April 2, 2020: MMWR Morb Mortal Wkly Rep 2020;69(14):422-426. https://doi.org/10.15585/mmwr.mm6914a4
11. Ferrer N, Longo M, Burnesono D. Coronavirus infection in pediatric emergency departments (CONFIDENCE) research group. Children with Covid-19 in pediatric emergency departments in Italy. N Eng J Med 2020;382(18):187-190. https://doi.org/10.1056/NEJMoa2006765
12. Qu H, Wu H, Dong L, Liu Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study. Lancet Infect Dis 2020;20(6):699-699. https://doi.org/10.1016/S1473-3099(20)30185-9
13. Smercon A, Bollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Natl Acad Sci U S A 2021;118(14):e2021111158. https://doi.org/10.1073/pnas.2021111158
14. Kam K, Yang CE, Cai L, et al. A well infant with coronavirus disease 2019 with high viral load. Clin Infect Dis 2020;71(15):e475-e476. https://doi.org/10.1093/cid/ciaa461
15. Hong H, Wang Y, Zhong HT, Chen CJ. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatr Neonatol 2020;61(2):131-132. https://doi.org/10.1111/pmn.12968
16. Besrod P. Why is COVID-19 so mild in children? Acta Paediatr 2020;109(12):1082-1083. https://doi.org/10.1111/apa.15371
17. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109(10):1088-1095. https://doi.org/10.1111/apa.15370
18. Berenschot S, De A, Vicuña A, Naald gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020;323(23):2427. https://doi.org/10.1001/jama.2020.8707
19. Radzikowska U, Magde M, Tan G, et al. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertensive, and COVID-19 risk factors. Allergy 2020;1-37. https://doi.org/10.1111/all.14429
20. O'Neill LAJ, Netea MG. BCG-induced trained immunity: Can it offer protection against COVID-19? Nat Rev Immunol 2020;20:335-337. https://doi.org/10.1038/s41577-020-0373-y
21. Li X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Eng J Med 2020;382(17):1685-1685. https://doi.org/10.1056/NEJMoa2009723
22. Delftink RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC, Metropolitan Region. J Pediatr 2020;223:199-203. https://doi.org/10.1016/j.jpeds.2020.05.087

**Declaration.** None. **Acknowledgements.** None. **Author contributions.** Both authors contributed equally to the development of the manuscript. **Funding.** None. **Conflicts of interest.** None.
Review

44. Syndrome temporally associated with COVID-19. 2020.
Royal College of Paediatrics and Child Health. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort. https://doi.org/10.1136/bmj.m2094

45. Kawasaki-like multisystem inflammatory syndrome in children during COVID-19 pandemic. Lancet 2020;395(10237):1607-1608.

Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children in previously healthy children and adolescents in New York City. JAMA 2020;324(3):294.

Vo, Italy. medRxiv 2020:1-23.

28. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with COVID-19 infection: Different points from adults. Int J Infect Dis 2020;8(6):547-548.

27. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Respir Med 2020;8(6):547-548. https://doi.org/10.1016/S2213-2600(20)30228-9

26. Chan H, Gao J, Wang C, et al. Clinical characteristics and intratracheal vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet 2020;395(10220):809-815. https://doi.org/10.1016/S0140-6736(20)30803-0

25. Li Y, Zhu R, Zheng S, et al. Lack of vertical transmission of severe acute respiratory syndrome coronavirus 2, China. Emerg Infect Dis 2020;26(6):1335-1336. https://doi.org/10.3201/eid2606.200287

24. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 newborns born to mothers with 2019-nCoV pneumonia. Transl Pediatr 2020;9(1):60. https://doi.org/10.21037/tp.2020.02.06

23. Penfold CA, Brubaker SG, Lanyon MA, et al. Detection of severe acute respiratory syndrome coronavirus 2 in placental and fetal membrane samples. Am J Obstet Gynecol MFM 2020;2:1-2. https://doi.org/10.1016/j.amjmgm.2020.100133

22. Zeng H, Xu X, Fan J, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA Pediatr 2020;174(9):773-774. https://doi.org/10.1001/jamapediatrics.2020.0693

21. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynecol Obstet 2020;149(1):130-136. https://doi.org/10.1016/j.ijgo.2020.03.069.3

20. Edwards-M. Coronavirus disease 2019 (COVID-19): Considerations in children. UpToDate 2020. https://doi.org/10.1016/j.ijgo.2020.03.069

19. Xie W, Zhao J, Gao Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol 2020;55(5):1169-1174. https://doi.org/10.1002/ppul.24718

18. Wise J. Covid-19 in no worse in immunocompromised children, says NICE. BMJ 2020;369:m1802. https://doi.org/10.1136/bmj.m1802

17. Baldamus A, Bittu R, Rovelli A, et al. Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and humaino-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Eur J Paediatr. Jau Marron Transplant 2020:6. https://doi.org/10.1002/10.0895-4

16. Viner RM, Russell SJ, Croker H, et al. School closure and management practices during coronavirus outbreaks including COVID-19: A rapid systematic review. Lancet Child Adolesc Health 2020;4(5):397-404. https://doi.org/10.1016/S2213-2600(20)30205-X

15. South African Paediatrics: Association Position Statement: Return of South African children to school. 2020. https://www.westonlinewesterncape.gov.za/documents/Back%20to%20School%20Position%20Statement.pdf (accessed 5 August 2020).

14. Centers for Disease Control and Prevention. Use cloth face coverings to help slow spread. 2020. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/diy-cloth-face-coverings.html (accessed 5 August 2020).

13. Van Brunselen L, Mutuza F, Cloete J, Amonu G, Geen RJ. What are we doing to the children of South Africa under the gaze of COVID-19 lockdown? S Afr Med J 2020;109(7):574-575. https://doi.org/10.7196/SAMJ.2020.v110i7.14932

12. Goga A, Chirinda W, Nganji NK, et al. Closing the gaps to eliminate mother-to-child transmission of HIV in South Africa. Int J Gynaecol Obstet 2020;23(1):137-143.

11. Viner RM, Russell SJ, Croker H, et al. School closure and management practices during coronavirus outbreaks including COVID-19: A rapid systematic review. Lancet Child Adolesc Health 2020;4(5):397-404. https://doi.org/10.1016/S2213-2600(20)30205-X

10. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Resp Med 2020;8(6):547-548. https://doi.org/10.1016/S2213-2680(20)30228-9

9. Yancey CW. COVID-19 and African Americans. JAMA 2020;323(19):1891. https://doi.org/10.1001/jama.2020.100133

8. Van Bruwaene L, Mustafa F, Cloete J, Ameena G, Green RJ. What are we doing to the children of South Africa under the gaze of COVID-19 lockdown? S Afr Med J 2020;109(7):574-575. https://doi.org/10.7196/SAMJ.2020.v110i7.14932

7. Western Cape Government. Covid-19 dashboard – Covid-19 response. 2020. https://www.westonlinewesterncape.gov.za/documents/Back%20to%20School%20Position%20Statement.pdf (accessed 5 August 2020).

6. Centers for Disease Control and Prevention. Use cloth face coverings to help slow spread. 2020. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/diy-cloth-face-coverings.html (accessed 5 August 2020).

5. Fore HH. A wake-up call: COVID-19 and its impact on children’s health and wellbeing. Lancet Glob Health 2020;8(6):e936-e940. https://doi.org/10.1016/S1473-3099(20)30644-5

4. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Resp Med 2020;8(6):547-548. https://doi.org/10.1016/S2213-2680(20)30228-9

3. Hall K, Sambre W. Income poverty, unemployment and social grants. S Afr Child Gauge Child Fam State 2020;56(1):1-24. https://doi.org/10.7196/SAMJ.2020.v110i7.14932

2. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Resp Med 2020;8(6):547-548. https://doi.org/10.1016/S2213-2680(20)30228-9

1. Western Cape Government. Covid-19 dashboard – Covid-19 response. 2020. https://www.westonlinewesterncape.gov.za/documents/Back%20to%20School%20Position%20Statement.pdf (accessed 5 August 2020).

0. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Resp Med 2020;8(6):547-548. https://doi.org/10.1016/S2213-2680(20)30228-9

September 2020, Vol. 110, No. 9